Reason

The Joyful Contrarianism of Gordon Tullock

WHAT KIND OF crank wants to put bayonets in steering wheels, praises political corruption as “working out rather well,” and thinks that competition can be harmful and should be discouraged? Gordon Tullock, the late George Mason University professor of law and economics, made all those arguments with a (more or less) straight face, while also helping invent the then-new discipline of sociobiology. His insights have proven to be more durable, and more sensible, than his many critics expected.

To be fair, economists tend to value counterintuitive arguments, where surprising conclusions emerge from innocuous assumptions. In 2019, we will pass the 70th anniversary of the Communist takeover of China, an event that Tullock witnessed in person from the vantage point of his diplomatic post in Tientsin. That experience launched his thinking about the problem of governance, anarchy, and the importance of rules. Looking back, many of the insights that powered his work from that time—once dismissed not just as counterintuitive but as outlandish—have now become conventional wisdom.

There are lots of contributions worth examining, including his work on voting, bureaucracy, and constitutional theory. But those fit reasonably well into the “public choice” tradition, which Tullock helped found, and are easily accessible to those interested in that approach. I will consider three of Tullock’s less well-known, but probably even more important, insights—regarding safety regulation, corruption, and the rationality of evolved behaviors—and see how this work has stood the test of time. The three are very different, but they are unified by one feature that is the hallmark of the economic approach: In every case, Tullock reached a conclusion but pressed further to ask, “And then what?”

SAFETY REGULATIONS

SHOULD GOVERNMENTS MANDATE more safety in products? The usual terms of debate weigh reduced injuries—the “human toll”—against increased cost, with only heartless “rational choice” trolls actually worrying much about costs. The idea that perfect safety is morally undesirable, because such policies have enormous opportunity costs, is obviously, annoyingly important—and a big part of the reason economists often end up standing alone at parties, studying the wallpaper pattern.

Safety is valuable, of course. But economists pitch their arguments “at the margin,” meaning for the last increment. The first improvements in safety are cheap and uncontroversial: reliable brakes, turn signals, seat belts, safety glass in windshields. The next increment—airbags, anti-lock braking systems—comes at much greater cost and with a smaller associated reduction in injuries. Ultimately, the only way to make cars completely safe is to park them and throw away the keys. Driving is dangerous.

Tullock’s contribution was to ask, “And then what?” The problem is worse, actually much worse, than the increasing marginal cost of safety improvements. The safety of the car, after all, is just one factor; drivers and their attitudes toward danger are the key missing variable. The state can only mandate the safety of the car. Ultimately, the driver’s behavior

You’re reading a preview, subscribe to read more.

More from Reason

Reason2 min readAmerican Government
Trump Doubles Down On Authoritarianism By Selecting J.d. Vance
IN SEPTEMBER 2021, Hillbilly Elegy author J.D. Vance—then still a long shot candidate for the Republican Senate nomination in Ohio—made an appearance on Fox News’ Tucker Carlson Tonight. In a crisp white button-down and navy blazer, no tie, he laid o
Reason17 min read
Fauci’s Pandemic
IN JUNE 2024, Anthony Fauci appeared before the House Select Subcommittee on the Coronavirus Pandemic for a contentious confrontation with congressional Republicans. But it opened on what might have sounded like an amicable note, as the subcommittee’
Reason3 min read
A Setback for MDMA-Assisted Psychotherapy
Source images: Chevron, Natural Resources Defense Council EFFORTS TO MAKE MDMA legally available as a psychotherapeutic catalyst hit a daunting roadblock in August. The Food and Drug Administration (FDA) declined to approve a new drug application sub

Related